Abdulkarim Najjar

Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment

Abdulkarim Najjar, Ans Punt, John F. Wambaugh et al. · Archives of Toxicology · 2022 · 42 citations · Full text

Pharmacy, Toxicology, Dose-response Modeling +10

Cosmetics Europe evaluation of 6 in silico skin penetration models

Sebastien Grégoire, Ian Sorrell, Daniela Lange et al. · Computational Toxicology · 2021 · 33 citations · Full text

Pharmacy, Dermatology, Toxicology +14

Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1

Abdulkarim Najjar, Charlott Platzer, Anton Luft et al. · European Journal of Medicinal Chemistry · 2018 · 24 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors

Tim Fischer, Thomas Krüger, Abdulkarim Najjar et al. · Bioorganic & Medicinal Chemistry Letters · 2017 · 23 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15

Next generation risk assessment: an ab initio case study to assess the systemic safety of the cosmetic ingredient, benzyl salicylate, after dermal exposure

Johanna Ebmeyer, Abdulkarim Najjar, Daniela Lange et al. · Frontiers in Pharmacology · 2024 · 22 citations · Full text

Pharmacy, Pharmacology, Toxicology +17